Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8742068 | 1.00 | MAPT (0.46) | MAPTHSD17B10ALDH1A1KDM4ETSHR | |
| SCHEMBL12226357 | 0.83 | MAPT (0.42) | MAPTALDH1A1KDM4ETSHRPOLB | |
| SCHEMBL16879998 | 0.83 | KDM4E (0.47) | HSD17B10ALDH1A1KDM4ETSHRPOLB | |
| SCHEMBL14622604 | 0.82 | ALDH1A1 (0.51) | MAPTALDH1A1KDM4ETSHRPOLB | |
| SCHEMBL31271545 | 0.81 | MAPT (0.45) | MAPTALDH1A1KDM4ETSHRPOLB | |
| SCHEMBL7763378 | 0.81 | HSD17B10 (0.47) | HSD17B10ALDH1A1KDM4E | |
| SCHEMBL27747933 | 0.81 | ALDH1A1 (0.40) | MAPTALDH1A1KDM4ETSHRALOX15 | |
| Tetraxetan SCHEMBL5370171 | 0.79 | HSD17B10 (0.58) | MAPTHSD17B10ALDH1A1KDM4E | |
| SCHEMBL6848102 | 0.79 | HSD17B10 (0.64) | MAPTHSD17B10ALDH1A1KDM4ETSHR | |
| Tetraxetan SCHEMBL18018 | 0.79 | HSD17B10 (0.64) | MAPTHSD17B10ALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173715-A2 | USE OF PIPERIDINE DERIVATIVES AS AGONISTS OF CHEMOKINE RECEPTOR ACTIVITY | Euroscreen S.A. (BE) | 2010-04-14 | — | — | EP | disclosed |
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
| WO-2009010478-A2 | USE OF PIPERIDINE DERIVATIVES AS AGONISTS OF CHEMOKINE RECEPTOR ACTIVITY | EUROSCREEN S.A. (BE) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | ACKR3, CCR5, CCR7 | MAPT 4701/4885HSD17B10 3983/4885ALDH1A1 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.